Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-018 in Advanced Solid Tumors and Hematological Malignancies
NCT05338346Phase 1Terminated
- Sponsor
- Antengene
- Start
- Jul 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ATG-018 in solid tumor (advanced stage) and hematological malignancies, sponsored by Antengene. Primary endpoints: Adverse Events and Serious Adverse Events at 12 months, Maximum Tolerated Dose at 12 months and 1 more. Started Jul 2022; status: terminated.
02
Drugs
ATG-018
03
Conditions
solid tumor (advanced stage)hematological malignancies
Beyond the preview
Go deeper on NCT05338346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05338346.